Lv59
1148 积分 2026-04-08 加入
Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial
11天前
已完结
Dalpiciclib plus endocrine therapy in women with HR+/HER2− advanced breast cancer and visceral crisis: a multicenter, nonrandomized, phase 2 DARVIN trial
17天前
已完结
Safety and antitumor activity of the first-in-class EGFR–HER3 bispecific antibody–drug conjugate iza-bren (BL-B01D1) in patients with pretreated locally advanced or metastatic breast cancer: a phase 1b study
27天前
已完结
Efficacy and Safety of BL-B01D1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma: A Phase II Clinical Trial
1个月前
已完结
Antibody-drug conjugates in breast cancer: from mechanism to revolutionizing clinical practice
1个月前
已完结
Current and future therapies for triple-negative breast cancer
1个月前
已完结
Izalontamab Brengitecan (Iza-Bren), a First-in-Class EGFR-HER3 Bispecific Antibody-Drug Conjugate in Extensive-Stage Small Cell Lung Cancer: Results From a Phase Ib Study
1个月前
已完结
Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody–drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials
1个月前
已完结
Izalontamab brengitecan, an EGFR and HER3 bispecific antibody–drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China
1个月前
已完结
The EGFR/ErbB Family in Breast Cancer: From Signalling to Therapy
1个月前
已完结
皖公网安备34019202002308
